Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds.

Kaufman M, Cruz A, Thompson J, Reddy S, Bansal N, Cohen JG, Wu Y, Vadgama J, Farias-Eisner R.

J Cancer Metastasis Treat. 2019;5. pii: 13. doi: 10.20517/2394-4722.2018.25. Epub 2019 Feb 27.

2.

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.

Keung MYT, Wu Y, Vadgama JV.

J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435. Review.

3.

Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance.

Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y.

Sci Rep. 2019 Mar 26;9(1):5141. doi: 10.1038/s41598-019-41672-6.

4.

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.

Nava M, Dutta P, Zemke NR, Farias-Eisner R, Vadgama JV, Wu Y.

BMC Med Genomics. 2019 Feb 8;12(1):32. doi: 10.1186/s12920-019-0477-8.

5.

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment.

Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J.

Oncotarget. 2018 Sep 21;9(74):33912-33930. doi: 10.18632/oncotarget.26089. eCollection 2018 Sep 21.

6.

Flexible ureteroscopic holmium laser lithotripsy with PolyScope for senile patients with renal calculi.

Xu K, Ding J, Shi B, Wu Y, Huang Y.

Exp Ther Med. 2018 Sep;16(3):1723-1728. doi: 10.3892/etm.2018.6369. Epub 2018 Jun 28.

7.

Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV.

J Cancer Res Oncobiol. 2018;1(2). pii: 107. doi: 10.31021/jcro.20181107. Epub 2018 Feb 27.

8.

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.

Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV.

Breast Cancer Res Treat. 2018 Aug;170(3):477-486. doi: 10.1007/s10549-018-4760-8. Epub 2018 Mar 28.

9.

Time to Clinical Follow-up after Abnormal Mammogram among African American and Hispanic Women.

Petersen SS, Sarkissyan M, Wu Y, Clayton S, Vadgama JV.

J Health Care Poor Underserved. 2018;29(1):448-462. doi: 10.1353/hpu.2018.0030.

10.

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.

Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R.

Int J Mol Sci. 2017 Nov 2;18(11). pii: E2305. doi: 10.3390/ijms18112305.

11.

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women.

Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV.

Cancers (Basel). 2017 Oct 24;9(10). pii: E144. doi: 10.3390/cancers9100144.

12.

GROα overexpression drives cell migration and invasion in triple negative breast cancer cells.

Bhat K, Sarkissyan M, Wu Y, Vadgama JV.

Oncol Rep. 2017 Jul;38(1):21-30. doi: 10.3892/or.2017.5668. Epub 2017 May 24.

13.

A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.

Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV.

Breast Cancer Res Treat. 2017 Jun;163(3):449-460. doi: 10.1007/s10549-017-4211-y. Epub 2017 Mar 23.

14.

Epithelial-Mesenchymal Transition and Breast Cancer.

Wu Y, Sarkissyan M, Vadgama JV.

J Clin Med. 2016 Jan 26;5(2). pii: E13. doi: 10.3390/jcm5020013. Review.

15.

Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.

Zheng S, Liu J, Wu Y, Huang TL, Wang G.

Future Med Chem. 2015;7(18):2485-505. doi: 10.4155/fmc.15.159. Epub 2015 Dec 16. Review.

16.

Slug contributes to cancer progression by direct regulation of ERα signaling pathway.

Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y, Vadgama JV.

Int J Oncol. 2015 Apr;46(4):1461-72. doi: 10.3892/ijo.2015.2878. Epub 2015 Feb 5.

17.

Epigenetics in breast and prostate cancer.

Wu Y, Sarkissyan M, Vadgama JV.

Methods Mol Biol. 2015;1238:425-66. doi: 10.1007/978-1-4939-1804-1_23. Review.

18.

Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells.

Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV.

RSC Adv. 2014 Aug 5;4(66):35242-35250.

19.

IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion.

Sarkissyan S, Sarkissyan M, Wu Y, Cardenas J, Koeffler HP, Vadgama JV.

PLoS One. 2014 Jul 25;9(7):e103534. doi: 10.1371/journal.pone.0103534. eCollection 2014.

20.

Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice.

Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV.

BMC Cancer. 2014 Apr 17;14:266. doi: 10.1186/1471-2407-14-266.

Supplemental Content

Loading ...
Support Center